Could some esophageal cancer patients skip surgery? new trial tests a less invasive option
NCT ID NCT07162506
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at two approaches for people with a type of esophageal cancer that shrank after initial chemo-immunotherapy. One group will have surgery to remove the tumor, while the other will get a combination of radiation and chemotherapy instead. Both groups will also receive maintenance immunotherapy for up to a year. The goal is to see if the non-surgical approach can control the cancer just as well while possibly avoiding the risks of major surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Camrelizumab (immunotherapy), nab-paclitaxel (chemotherapy), carboplatin (chemotherapy), radiotherapy (radiation)
- What this could lead to
- If successful, this could show that some esophageal cancer patients can avoid major surgery and still control their disease with a combination of radiation, chemo, and immunotherapy.
- What could go wrong
- This is a Phase II trial with only 120 participants, so results are preliminary. The non-surgery group may have higher recurrence rates, and side effects from radiation and immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?